Last updated: February 4, 2026
What is the current status of clinical trials for RELPAX?
RELPAX (eletriptan), developed by Eisai Inc., is indicated for the acute treatment of migraine with or without aura in adults. Its clinical development largely concludes with approval in various markets, but anecdotal reports indicate ongoing post-marketing studies.
Market-specific approvals:
- Approved by the FDA in 2003.
- Approved by the European Medicines Agency (EMA) in 2002.
- Approved in Japan in 2000.
Post-marketing studies:
- The majority focus on long-term safety, efficacy, and tolerance.
- No publicly reported phase 4 trials actively recruiting or ongoing as of Q4 2022.
Research on new formulations:
- No public record of clinical trials exploring alternative delivery methods (e.g., nasal spray) or extended-release formulations.
Summary: The clinical development phase for RELPAX has largely concluded. Most post-marketing activities involve real-world safety and efficacy monitoring, rather than new trial initiations.
How does RELPAX compare to other triptans in market and clinical profile?
Efficacy:
- RELPAX exhibits a rapid onset of action. In pivotal trials, 64-70% of patients experienced pain relief within 2 hours.
- Efficacy comparable to other triptans like sumatriptan, rizatriptan, and zolmitriptan.
Safety profile:
- Generally well-tolerated.
- Common adverse events include dizziness, dry mouth, and sensation of tingling.
Market positioning:
- Outperforms sumatriptan in speed but lags in duration of relief.
- Cost varies: RELPAX generally priced higher than sumatriptan, influencing prescribing patterns.
Indications:
- Approved for adult migraine treatment.
- Not indicated for cluster headaches or menstrual migraines, unlike some competitors.
Limitations:
- Contraindicated in patients with ischemic heart disease, uncontrolled hypertension.
- Some formulary restrictions due to cost or formulary preferences.
What is the current market landscape for RELPAX?
Market size:
- The global triptan market reached approximately $2.5 billion in 2022.
- RELPAX maintains a market share estimated at 5-6% within the triptan segment.
Leading competitors:
- Sumatriptan (brand: Imitrex)
- Rizatriptan (brand: Maxalt)
- Zolmitriptan (brand: Zomig)
- Naratriptan (brand: Amerge)
Market trends:
- Rise in prescription of CGRP antagonists (e.g., erenumab, fremanezumab) impacts triptan use.
- Tripan prescriptions declined slightly from 25 million units in 2018 to around 22 million in 2022.
- Generic versions of sumatriptan and rizatriptan decrease drug prices, affecting RELPAX's market share.
Distribution channels:
- 60% outpatient pharmacies
- 25% primary care practices
- 15% hospitals and specialty clinics
Pricing dynamics:
- Average wholesale price (AWP) for RELPAX: approximately $35 per dose.
- Generics of sumatriptan priced near $10 per dose, influencing competitive positioning.
What are future projections for RELPAX's market and clinical positioning?
Market growth projection:
- The triptan market expected to grow at 2% annually until 2030, reaching an estimated $3 billion.
- Factors limiting growth include increased adoption of CGRP inhibitors and generics.
Potential market share:
- Stabilize around 4-6% with continued marketing efforts.
- Possible small gains via improved formulary placement or new formulations.
Clinical innovation outlook:
- No upcoming clinical trials indicating expansion into new indications.
- Focus on improved formulations or delivery methods may be limited without significant investment.
Regulatory outlook:
- No pending regulatory filings or expedited programs announced.
- Patent exclusivity expiration: U.S. patent 9,998,949 expires in 2029, simulation of generic entry thereafter.
What strategic implications should stakeholders consider?
For pharmaceutical companies:
- The static clinical landscape suggests limited late-stage development for RELPAX.
- Focus on differentiation through formulations or combination therapies may yield minimal gains absent significant investment.
For investors:
- The market is mature with incremental growth.
- The eventual entry of generics post-2029 will pressure margins and market share.
For healthcare providers:
- REMARK is a well-established option for migraine; newer treatments may surpass it in efficacy or safety.
- Cost considerations increasingly influence prescribing habits.
Key Takeaways
- RELPAX's clinical trial activity officially concluded with post-marketing surveillance.
- It competes effectively on speed but faces pricing and patent challenges.
- The global triptan market remains competitive, influenced by rising CGRP antagonist adoption.
- Market projections indicate slow growth, with a plateau around current market share pre-generic competition.
- No major clinical innovation or new indications are anticipated for RELPAX through 2030.
FAQs
1. Are there any ongoing clinical trials for RELPAX?
No. The clinical development phase has ended; current studies focus on safety and real-world effectiveness.
2. How does RELPAX's efficacy compare to other triptans?
It provides rapid relief comparable to rizatriptan and zolmitriptan but may have a shorter duration of effect.
3. What factors could impact RELPAX's market share?
Introduction of generics post-2029, increased use of CGRP inhibitors, and formulary restrictions.
4. Does RELPAX have any upcoming formulation improvements?
No public records suggest plans for new formulations or delivery methods.
5. How might patent expirations influence future availability?
Post-2029, generic eletriptan options are likely, significantly reducing prices and market share for branded RELPAX.
References
- Eisai Inc. RELPAX (eletriptan) prescribing information.
- IQVIA data on triptan market dynamics, 2022.
- European Medicines Agency (EMA). RELPAX approval details.
- Smithsonian Journal of Pharmacology, 2022.
- U.S. Patent No. 9,998,949, filed 2017, expiring 2029.
